Physician

Mahender Reddy Yellu, MD

According to 2025 Medicare claims, Mahender Yellu, MD (NPI: 1659510337) practices medical oncology in the Sebring, FL market, with the plurality of this provider's patient population coming from Highlands, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33870-1204.

Yellu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,375 traditional Medicare patients, billed 387,908 HCPCS/CPT codes, and received $5,553,114 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,837 prescription claims across 399 beneficiaries totaling $5,540,784 in drug costs, led by Revlimid (Lenalidomide). DME data shows 62 claims. Open Payments data shows 231 records totaling $16,451. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $19,848 to $5,553,114. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,028 to $5,540,784. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	91	228	$19,848
2016	N/R	N/R	N/R
2017	62	371	$28,516
2018	474	46,840	$567,299
2019	949	226,371	$2,651,669
2020	935	288,471	$3,548,153
2021	1,072	240,758	$3,889,201
2022	1,232	365,278	$4,761,280
2023	1,254	401,959	$5,845,923
2024	1,375	387,908	$5,553,114

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	25	47	$3,028
2016	13	32	$1,597
2017	14	26	$980
2018	40	89	$49,539
2019	143	504	$745,714
2020	188	844	$2,035,804
2021	237	1,060	$2,587,549
2022	337	1,599	$4,478,020
2023	334	1,588	$4,605,539
2024	399	1,837	$5,540,784

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	47	$4,777
2021	N/R	60	$4,628
2022	N/R	111	$3,825
2023	N/R	68	$11,813
2024	N/R	62	$1,510

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	631	2,050	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	223	314	$13
96372	Injection of drug or substance under skin or into muscle	335	1,173	$10
36415	Insertion of needle into vein for collection of blood sample	867	2,417	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	849	2,685	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	72	1,897	$1,151,532
Xtandi	Enzalutamide	49	1,470	$677,720
Nubeqa	Darolutamide	34	1,020	$463,863
Vonjo	Pacritinib Citrate	13	390	$326,019
Calquence	Acalabrutinib Maleate	19	570	$292,436

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	29	$1,121
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	33	$389

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	231	$16,451	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mahender Reddy Yellu, MD?

Tedicare shows public-source Medicare data for Mahender Reddy Yellu, MD (NPI 1659510337), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mahender Reddy Yellu, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mahender Reddy Yellu, MD?

Mahender Reddy Yellu, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Mahender Reddy Yellu, MD have Open Payments data?

Mahender Reddy Yellu, MD has 231 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.